GSK's Big Reveal: An R&D Overhaul Poised To Yield Long-Term Cultural Change
With few near-term catalysts, GSK's R&D strategy may leave some investors underwhelmed, but President-R&D Hal Barron is focused on making deep cultural and scientific changes at the big pharma. He laid out his initial turnaround plan July 25.
You may also be interested in...
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.
GSK said its oncology pipeline has doubled in size since July to include 16 assets in the clinic and highlighted the newly in-licensed bifunctional immunotherapy M7824.
Pfizer CEO Ian Read will preside over his last sales and earnings call as the big pharma's chief executive, while for GlaxoSmithKline, uncertainty lingers over the timing of a generic Advair. Amgen will have its second opportunity to talk to investors about its 60% Repatha price cut, while answering questions about Aimovig strategy and Neulasta biosimilars. And other topics to watch in the next earnings calls...